Yazen Raises €50M for Digital Health Growth

Yazen, a prominent digital health provider headquartered in Lund, Sweden, has successfully closed its most substantial funding round to date, securing €50 million. This significant capital injection, announced on October 8, 2026, was spearheaded by European growth equity firm Verdane, with crucial participation from existing backer Evli Growth Partners. The investment underscores the escalating investor confidence in digital-first solutions for chronic condition management.

The company has carved a niche in the digital weight-loss care sector, integrating advanced pharmacological treatments with comprehensive, continuous digital support. Patients benefit from a dedicated, multidisciplinary healthcare team, comprising physicians, registered dietitians, psychologists, and physiotherapists, all accessible through its innovative platform. Since its inception in 2021, founded by Fredrik Meurling (CEO), Magnus Nyhlén, and Martin Carlsson, Yazen has rapidly expanded its footprint across eight key European markets, including Sweden, Norway, Denmark, the Netherlands, the United Kingdom, Germany, Switzerland, and Spain.

Yazen's operational success is evidenced by its impressive growth trajectory. The platform currently supports over 50,000 active patients, having assisted more than 70,000 individuals in total. In the fiscal year 2025, the company nearly doubled its revenue, achieving €29.4 million, with its annual recurring revenue (ARR) at year-end reaching SEK 372 million, equivalent to approximately €31.5 million. This robust financial performance highlights the market's strong demand for Yazen's integrated care model.

This latest funding infusion is earmarked for accelerating Yazen's European expansion initiatives and scaling its operational capabilities. Furthermore, the company intends to broaden its therapeutic scope, venturing into adjacent cardiometabolic care areas. This strategic diversification aligns with the broader trend in digital health towards holistic patient management for complex, interconnected conditions.

Prior to this Series B+ round, Yazen had already established a solid financial foundation. It previously raised €19.5 million in a Series A round during late 2024 and secured a €6.5 million credit facility from HSBC Innovation Banking in early 2026. The company's earlier investors, who continue to support its vision, include Luminar Ventures, Aggregate Media, Fåhraeus Startup and Growth, Helsana HealthInvest, Almaz Capital, and Yabeo. The consistent backing from a diverse group of investors reflects a shared belief in Yazen's disruptive potential within the healthcare industry.

The digital health sector, particularly segments focused on chronic disease management and preventative care, continues to attract substantial investment. Yazen's success story is emblematic of this trend, showcasing how technology-enabled, patient-centric care models can achieve significant scale and impact. The company's expansion into cardiometabolic health could position it as a key player in addressing the growing burden of conditions like diabetes and heart disease across Europe.